Download PDF
Semin Liver Dis 2014; 34(02): 123-133
DOI: 10.1055/s-0034-1375954
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genetic Basis of Drug-Induced Liver Injury: Present and Future

Thomas J. Urban
1   Center for Human Genome Variation, Duke University Medical Center, Durham, North Carolina
,
Ann K. Daly
2   Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, United Kingdom
,
Guruprasad P. Aithal
3   National Institute for Health Research Nottingham Digestive Diseases Biomedical research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2014 (online)

    Permissions and Reprints

Abstract

There is considerable evidence that susceptibility to idiosyncratic drug-induced liver injury (DILI) is genetically determined. Though genetic associations with DILI have been reported since the 1980s, the development of genome-wide association studies has enabled genetic risk factors for DILI, in common with other diseases, to be detected and confirmed more confidently. Human leukocyte antigen (HLA) genotype has been demonstrated to be a strong risk factor for development of DILI with a range of drugs and the underlying mechanism, probably involving presentation of a drug-peptide complex to T cells is increasingly well understood. However, specific HLA alleles are not associated with all forms of DILI and non-HLA genetic risk factors, especially those relating to drug disposition, also appear to contribute. For some drugs, there is evidence of a dual role for HLA and drug metabolism genes. Though the associations with non-HLA genes have been less well replicated than the HLA associations, there is increasing evidence that drug metabolism genes such as NAT2 and UGT2B7 contribute to some forms of DILI. Translating current genetic findings on DILI susceptibility to the clinic has been relatively slow, but some progress is now being made. In the future, DNA sequencing may lead to the identification of rare variants that contribute to DILI. Developments in the related area of epigenomics and in the development of improved models for DILI by use of genetically defined induced pluripotent stem cells should improve understanding of the biology of DILI and inform drug development.

Keywords

human leukocyte antigen - genome-wide association study - candidate gene study - cytochrome P450 - N-acetyltransferase - UDP-glucuronosyltransferase - ABC transporter
 

  • References

  • 1 Wilke RA, Lin DW, Roden DM , et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6 (11) 904-916
    CrossrefPubMedGoogle Scholar
  • 2 Ostapowicz G, Fontana RJ, Schiødt FV , et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137 (12) 947-954
    CrossrefPubMedGoogle Scholar
  • 3 Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5 (9) 669-676
    CrossrefPubMedGoogle Scholar
  • 4 Urban TJ, Shen Y, Stolz A , et al; Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22 (11) 784-795
    CrossrefPubMedGoogle Scholar
  • 5 Wellcome Trust Case Control C ; Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447 (7145) 661-678
    CrossrefPubMedGoogle Scholar
  • 6 McCarthy MI, Abecasis GR, Cardon LR , et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9 (5) 356-369
    CrossrefPubMedGoogle Scholar
  • 7 Daly AK, Donaldson PT, Bhatnagar P , et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41 (7) 816-819
    CrossrefPubMedGoogle Scholar
  • 8 Monshi MM, Faulkner L, Gibson A , et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57 (2) 727-739
    CrossrefPubMedGoogle Scholar
  • 9 Wuillemin N, Adam J, Fontana S, Krähenbühl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013; 190 (10) 4956-4964
    CrossrefPubMedGoogle Scholar
  • 10 Hautekeete ML, Horsmans Y, Van Waeyenberge C , et al. HLA association of amoxicillin-clavulanate—induced hepatitis. Gastroenterology 1999; 117 (5) 1181-1186
    CrossrefPubMedGoogle Scholar
  • 11 O'Donohue J, Oien KA, Donaldson P , et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47 (5) 717-720
    CrossrefPubMedGoogle Scholar
  • 12 Lucena MI, Molokhia M, Shen Y , et al; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141 (1) 338-347
    CrossrefPubMedGoogle Scholar
  • 13 Donaldson PT, Daly AK, Henderson J , et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53 (6) 1049-1053
    CrossrefPubMedGoogle Scholar
  • 14 Kindmark A, Jawaid A, Harbron CG , et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8 (3) 186-195
    CrossrefPubMedGoogle Scholar
  • 15 Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25 (10) 1057-1064
    CrossrefPubMedGoogle Scholar
  • 16 Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67 (1) 101-154
    CrossrefPubMedGoogle Scholar
  • 17 Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 2006; 7 (6) 889-908
    CrossrefPubMedGoogle Scholar
  • 18 Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ ; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007; 150 (6) 808-815
    CrossrefPubMedGoogle Scholar
  • 19 Aithal GP, Day CP, Leathart JBS, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10 (6) 511-518
    CrossrefPubMedGoogle Scholar
  • 20 Markova SM, De Marco T, Bendjilali N , et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther 2013; 94 (6) 678-686
    CrossrefPubMedGoogle Scholar
  • 21 Ariyoshi N, Iga Y, Hirata K , et al. Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese. Drug Metab Pharmacokinet 2010; 25 (3) 298-306
    CrossrefPubMedGoogle Scholar
  • 22 Yimer G, Amogne W, Habtewold A , et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012; 12 (6) 499-506
    CrossrefPubMedGoogle Scholar
  • 23 Metushi IG, Sanders C, Lee WM, Uetrecht J ; Acute Liver Study Group. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 2014; 59 (3) 1084-1093
    CrossrefPubMedGoogle Scholar
  • 24 Huang YS, Chern HD, Su WJ , et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37 (4) 924-930
    CrossrefPubMedGoogle Scholar
  • 25 Cho HJ, Koh WJ, Ryu YJ , et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87 (6) 551-556
    CrossrefPubMedGoogle Scholar
  • 26 Kim SH, Kim SH, Bahn JW , et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10 (11) 1767-1779
    CrossrefPubMedGoogle Scholar
  • 27 Vuilleumier N, Rossier MF, Chiappe A , et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62 (6) 423-429
    CrossrefPubMedGoogle Scholar
  • 28 Yamada S, Tang M, Richardson K , et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10 (9) 1433-1445
    CrossrefPubMedGoogle Scholar
  • 29 Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26 (2) 312-318
    CrossrefPubMedGoogle Scholar
  • 30 Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK , et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 2013; 17 (4) 499-504
    CrossrefPubMedGoogle Scholar
  • 31 Gupta VH, Amarapurkar DN, Singh M , et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 2013; 28 (8) 1368-1374
    CrossrefPubMedGoogle Scholar
  • 32 Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park BK. Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 2010; 31 (7) 367-395
    CrossrefPubMedGoogle Scholar
  • 33 Acuña G, Foernzler D, Leong D , et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2002; 2 (5) 327-334
    CrossrefPubMedGoogle Scholar
  • 34 Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132 (1) 272-281
    CrossrefPubMedGoogle Scholar
  • 35 Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011; 89 (6) 911-914
    CrossrefPubMedGoogle Scholar
  • 36 Eichelbaum M, Musch E, Castroparra M, Vonsassen W. Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J Clin Pharmacol 1982; 14 (4) 575 –P576
    PubMedGoogle Scholar
  • 37 Grönhagen-Riska C, Hellstrom PE, Fröseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118 (3) 461-466
    PubMedGoogle Scholar
  • 38 Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 1981; 3 (3) 271-279
    CrossrefPubMedGoogle Scholar
  • 39 Mitchell JR, Thorgeirsson UP, Black M , et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18 (1) 70-79
    PubMedGoogle Scholar
  • 40 Ohno M, Yamaguchi I, Yamamoto I , et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4 (3) 256-261
    PubMedGoogle Scholar
  • 41 Huang YS, Chern HD, Su WJ , et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35 (4) 883-889
    CrossrefPubMedGoogle Scholar
  • 42 Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14 (5) 622-626
    PubMedGoogle Scholar
  • 43 Ho HT, Wang TH, Hsiong CH , et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics 2013; 23 (4) 200-207
    CrossrefPubMedGoogle Scholar
  • 44 Possuelo LG, Castelan JA, de Brito TC , et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64 (7) 673-681
    CrossrefPubMedGoogle Scholar
  • 45 Bozok Cetintaş V, Erer OF, Kosova B , et al. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 2008; 56 (1) 81-86
    PubMedGoogle Scholar
  • 46 Chamorro JG, Castagnino JP, Musella RM , et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol 2013; 28 (2) 323-328
    CrossrefPubMedGoogle Scholar
  • 47 Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R , et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011; 15 (10) 1403-1408
    CrossrefPubMedGoogle Scholar
  • 48 Saukkonen JJ, Cohn DL, Jasmer RM , et al; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174 (8) 935-952
    CrossrefPubMedGoogle Scholar
  • 49 Roy B, Chowdhury A, Kundu S , et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16 (9) 1033-1037
    CrossrefPubMedGoogle Scholar
  • 50 Huang YS, Su WJ, Huang YH , et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47 (1) 128-134
    CrossrefPubMedGoogle Scholar
  • 51 Leiro V, Fernández-Villar A, Valverde D , et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28 (6) 835-839
    CrossrefPubMedGoogle Scholar
  • 52 Simon T, Becquemont L, Mary-Krause M , et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67 (4) 432-437
    CrossrefPubMedGoogle Scholar
  • 53 Watanabe I, Tomita A, Shimizu M , et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003; 73 (5) 435-455
    CrossrefPubMedGoogle Scholar
  • 54 Lucena MI, Andrade RJ, Martínez C , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008; 48 (2) 588-596
    CrossrefPubMedGoogle Scholar
  • 55 Okada R, Maeda K, Nishiyama T , et al. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone. Drug Metab Dispos 2011; 39 (12) 2290-2297
    CrossrefPubMedGoogle Scholar
  • 56 Lucena MI, García-Martín E, Andrade RJ , et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 2010; 52 (1) 303-312
    CrossrefPubMedGoogle Scholar
  • 57 Andrews E, Armstrong M, Tugwood J , et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010; 51 (5) 1656-1664
    CrossrefPubMedGoogle Scholar
  • 58 Kuehl P, Zhang J, Lin Y , et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27 (4) 383-391
    CrossrefPubMedGoogle Scholar
  • 59 Li T, Yu RT, Atkins AR, Downes M, Tukey RH, Evans RM. Targeting the pregnane X receptor in liver injury. Expert Opin Ther Targets 2012; 16 (11) 1075-1083
    CrossrefPubMedGoogle Scholar
  • 60 Li F, Lu J, Cheng J , et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 2013; 19 (4) 418-420
    CrossrefPubMedGoogle Scholar
  • 61 Ahmadian M, Suh JM, Hah N , et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 2013; 19 (5) 557-566
    CrossrefPubMedGoogle Scholar
  • 62 Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773 (3) 283-308
    CrossrefPubMedGoogle Scholar
  • 63 Noe J, Kullak-Ublick GA, Jochum W , et al. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol 2005; 43 (3) 536-543
    CrossrefPubMedGoogle Scholar
  • 64 Lang C, Meier Y, Stieger B , et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17 (1) 47-60
    CrossrefPubMedGoogle Scholar
  • 65 Bhatnagar P, Day CP, Aithal G , et al. Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology 2008; 253 (1–3) 10
    CrossrefPubMedGoogle Scholar
  • 66 Haenisch S, Zimmermann U, Dazert E , et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7 (1) 56-65
    CrossrefPubMedGoogle Scholar
  • 67 Choi JH, Ahn BM, Yi J , et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007; 17 (6) 403-415
    CrossrefPubMedGoogle Scholar
  • 68 Haas DW, Bartlett JA, Andersen JW , et al; Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43 (6) 783-786
    CrossrefPubMedGoogle Scholar
  • 69 Ritchie MD, Haas DW, Motsinger AA , et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2006; 43 (6) 779-782
    CrossrefPubMedGoogle Scholar
  • 70 Yuan J, Guo S, Hall D , et al; Nevirapine Toxicogenomics Study Team. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25 (10) 1271-1280
    CrossrefPubMedGoogle Scholar
  • 71 Holmes MV, Casas JP, Hingorani AD. Putting genomics into practice. BMJ 2011; 343: d4953
    CrossrefPubMedGoogle Scholar
  • 72 Aithal GP, Watkins PB, Andrade RJ , et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6) 806-815
    CrossrefPubMedGoogle Scholar
  • 73 Olson H, Betton G, Robinson D , et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32 (1) 56-67
    CrossrefPubMedGoogle Scholar
  • 74 Mallal S, Phillips E, Carosi G , et al; PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358 (6) 568-579
    CrossrefPubMedGoogle Scholar
  • 75 El Sherrif Y, Potts JR, Howard MR , et al. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations?. Liver Int 2013; 33 (8) 1266-1270
    CrossrefPubMedGoogle Scholar
  • 76 Alfirevic A, Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012; 92 (3) 376-380
    CrossrefPubMedGoogle Scholar
  • 77 Chen P, Lin JJ, Lu CS , et al; Taiwan SJS Consortium. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364 (12) 1126-1133
    CrossrefPubMedGoogle Scholar
  • 78 Hung SI, Chung WH, Liou LB , et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102 (11) 4134-4139
    CrossrefPubMedGoogle Scholar
  • 79 Kazeem GR, Cox C, Aponte J , et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009; 19 (9) 661-665
    CrossrefPubMedGoogle Scholar
  • 80 Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012; 92 (6) 757-765
    CrossrefPubMedGoogle Scholar
  • 81 Zhang FR, Liu H, Irwanto A , et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013; 369 (17) 1620-1628
    CrossrefPubMedGoogle Scholar
  • 82 Dubios PCA. Thiopurine induced pancreatitis genetics working group. The risk of azathioprine-induced pancreatitis depends on genetic variants in the HLA gene region. Gut 2011; 60: A60
    PubMedGoogle Scholar
  • 83 Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360 (17) 1696-1698
    CrossrefPubMedGoogle Scholar
  • 84 Maher B. Personal genomes: The case of the missing heritability. Nature 2008; 456 (7218) 18-21
    PubMedGoogle Scholar
  • 85 Chung WH, Hung SI, Hong HS , et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428 (6982) 486
    CrossrefPubMedGoogle Scholar
  • 86 Hughes AR, Spreen WR, Mosteller M , et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 2008; 8 (6) 365-374
    CrossrefPubMedGoogle Scholar
  • 87 Liu R, Paxton WA, Choe S , et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86 (3) 367-377
    CrossrefPubMedGoogle Scholar
  • 88 Samson M, Libert F, Doranz BJ , et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382 (6593) 722-725
    CrossrefPubMedGoogle Scholar
  • 89 Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 2008; 83 (3) 311-321
    CrossrefPubMedGoogle Scholar
  • 90 Bamshad MJ, Ng SB, Bigham AW , et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12 (11) 745-755
    CrossrefPubMedGoogle Scholar
  • 91 Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011; 12 (8) 529-541
    CrossrefPubMedGoogle Scholar
  • 92 Murphy SK, Yang H, Moylan CA , et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145 (5) 1076-1087
    CrossrefPubMedGoogle Scholar
  • 93 Greenbaum LE. From skin cells to hepatocytes: advances in application of iPS cell technology. J Clin Invest 2010; 120 (9) 3102-3105
    CrossrefPubMedGoogle Scholar
  • 94 Pariente EA, Hamoud A, Goldfain D , et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol 1989; 13 (10) 769-774
    PubMedGoogle Scholar
  • 95 Hirata K, Takagi H, Yamamoto M , et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8 (1) 29-33
    CrossrefPubMedGoogle Scholar
  • 96 Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci 2000; 45 (6) 1103-1108
    CrossrefPubMedGoogle Scholar
  • 97 Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166 (7) 916-919
    CrossrefPubMedGoogle Scholar
  • 98 Spraggs CF, Budde LR, Briley LP , et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29 (6) 667-673
    CrossrefPubMedGoogle Scholar
  • 99 Singer JB, Lewitzky S, Leroy E , et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42 (8) 711-714
    CrossrefPubMedGoogle Scholar
  • 100 Phillips E, Bartlett JA, Sanne I , et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013; 62 (2) e55-e57
    CrossrefPubMedGoogle Scholar
  • 101 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012; 44 (1) 116-126
    CrossrefPubMedGoogle Scholar